SIGA Technologies vs Tonix Pharmaceuticals
SIGA and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SIGA and TNXP compare
SIGA Technologies is the larger company, worth 3.8 times as much as Tonix Pharmaceuticals ($197M against $51.6M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (318% versus −69.6% for SIGA Technologies).
SIGA Technologies keeps more of each dollar of sales as profit, with a net margin of 1.3% compared with −420% at Tonix Pharmaceuticals.
SIGA Technologies pays a dividend yielding 21.9%; Tonix Pharmaceuticals does not pay one.
SIGA Technologies scores higher on the StockData Score (14 against 10 for Tonix Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SIGA | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $197M | $51.6M |
| Share price | $2.74 | $3.01 |
| Change, 1 year | −55.9% | −83.0% |
| Change, 5 years | −70.4% | −100.0% |
| Beta (5Y) | 1.08 | 2.01 |
| Employees | 49 | 142 |
| StockData Score | ||
| Total score | 14 (better) | 10 |
| Valuation score | 3 | 3 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/S | 3.8× | 1.2× (better) |
| P/B | 1.2× | 0.3× (better) |
| FCF yield | – | −329% |
| Fair value | $6.01 | $18.27 |
| Margin of safety | 54.4% | 83.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −69.6% | 318% (better) |
| Revenue growth, 5Y average | −5.4% | – |
| Net income growth (TTM) | −99.1% | – |
| EPS growth (TTM) | −100% | – |
| EPS growth, 5Y average | −14.7% | – |
| Profitability | ||
| Gross margin | 54.0% | 89.3% (better) |
| Operating margin | −14.2% (better) | −436% |
| Net margin | 1.3% (better) | −420% |
| FCF margin | – | −395% |
| Return on equity | 0.37% (better) | −84.1% |
| Return on invested capital | −15.0% (better) | −388% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 24.57 (better) | 4.57 |
| Altman Z-score | 13.18 (better) | −6.62 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 21.9% | – |
| Payout ratio | 6325% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | – | −288% |
| Shareholder yield | 21.9% (better) | −288% |
| Ownership | ||
| Held by institutions | 48.5% | 54.6% |
| Held by insiders | 1.9% | 0.27% |
| Insider net buying, 12 months | – | $479K |
| Short interest, % of float | 5.1% | 19.4% |
Go deeper
- SIGA stock overview
- SIGA income statement
- SIGA valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.